- Home
- MGRX vs MIRA Comparison
MGRX vs MIRA Comparison
Compare MGRX & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGRX
- MIRA
- Stock Information
- Founded
- MGRX 2021
- MIRA 2020
- Country
- MGRX United States
- MIRA United States
- Employees
- MGRX N/A
- MIRA N/A
- Industry
- MGRX Computer Software: Prepackaged Software
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- MGRX Technology
- MIRA Health Care
- Exchange
- MGRX Nasdaq
- MIRA Nasdaq
- Market Cap
- MGRX 7.0M
- MIRA 17.1M
- IPO Year
- MGRX 2023
- MIRA 2023
- Fundamental
- Price
- MGRX $2.50
- MIRA $1.05
- Analyst Decision
- MGRX
- MIRA Strong Buy
- Analyst Count
- MGRX 0
- MIRA 2
- Target Price
- MGRX N/A
- MIRA $14.00
- AVG Volume (30 Days)
- MGRX 1.0M
- MIRA 552.1K
- Earning Date
- MGRX 10-29-2024
- MIRA 11-11-2024
- Dividend Yield
- MGRX N/A
- MIRA N/A
- EPS Growth
- MGRX N/A
- MIRA N/A
- EPS
- MGRX N/A
- MIRA N/A
- Revenue
- MGRX $866,792.00
- MIRA N/A
- Revenue This Year
- MGRX N/A
- MIRA N/A
- Revenue Next Year
- MGRX N/A
- MIRA N/A
- P/E Ratio
- MGRX N/A
- MIRA N/A
- Revenue Growth
- MGRX 245.48
- MIRA N/A
- 52 Week Low
- MGRX $2.15
- MIRA $0.51
- 52 Week High
- MGRX $16.80
- MIRA $6.40
- Technical
- Relative Strength Index (RSI)
- MGRX 32.69
- MIRA 38.97
- Support Level
- MGRX $2.20
- MIRA $1.04
- Resistance Level
- MGRX $2.83
- MIRA $1.20
- Average True Range (ATR)
- MGRX 0.41
- MIRA 0.07
- MACD
- MGRX -0.06
- MIRA 0.02
- Stochastic Oscillator
- MGRX 8.44
- MIRA 19.44
About MGRX Mangoceuticals Inc.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.